Particularly, blocking and/or modifying agents that regulate sphingosine kinases (SphK1 and SphK2) and sphingosine-1-phosphate (S1P) receptor-signaling pathways have been intensively explored in breast cancer [3,4,5]. This evidence concerns the gene SPHK2 and breast carcinoma.